Use of spironolactone-based composition that exhibits an inhibitory action on T-lymphocyte activation which is useful for preventing and/or treating multiple sclerosis
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Dec 26, 2017
Grant Date -
Apr 10, 2014
app pub date -
Dec 12, 2013
filing date -
Oct 26, 2010
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention relates to the use of spironolactone for the preparation of a pharmaceutical composition intended for preventing and/or treating multiple sclerosis. Alternatively, the invention relates to the use of spironolactone directly in T-lymphocytes or dendritic cells obtained from a blood sample taken from a patient and then injected back into the circulation. Therefore, the present invention relates to the use of a composition comprising spironolactone that can be used in the treatment of multiple sclerosis, which covers the administration of spironolactone directly or lymphocytes pre-treated with spironolactone, or dendritic cells to individuals requiring such treatment. Spironolactone is an orally administered drug that is less expensive than many of the treatments available for MS and, furthermore, has the advantage of being a known compound already used in humans for extended periods and therefore the adverse effects thereof have been described in clinical studies.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully